WS #10503

From 500 msgs · 10 key-dev

Evercore ISI downgrades Nike to In Line, slashes price target to $46, citing weak wholesale trends and slow innovation. Pfizer's lung cancer therapy fails in late-stage trial versus chemotherapy.

Nike Downgrade by Evercore ISI

Evercore ISI downgrades Nike to In Line, slashes price target to $46, citing weak wholesale trends and slow innovation.

Pfizer's lung cancer therapy fails in late-stage trial versus chemotherapy.

Full world state #10503 →